New whooping cough vaccine passes major safety check in thousands of adults
NCT ID NCT06798831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large Phase 3 trial is testing the safety of a new recombinant pertussis (whooping cough) vaccine in 2,399 healthy adults aged 18 to 75. Participants receive a single booster dose, and researchers monitor for side effects over 28 days. The goal is to confirm the vaccine is safe and consistent across different manufacturing lots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant acellular pertussis (aP) vaccine (Pertagen®)
What this could lead to
If successful, this could provide a safer, well-tolerated whooping cough booster for adults, helping reduce spread and protect vulnerable populations.
What could go wrong
This is a safety-focused trial, not designed to prove effectiveness. Rare side effects may still emerge, and results may not apply to children or older adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS VACCINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chula Clinical Research Center (Chula CRC)
Bangkok, Bangkok, 10330, Thailand
-
Queen Saovabha Memorial Institute, Thai Red Cross Society
Bangkok, Bangkok, 10330, Thailand
-
Thai Red Cross AIDS and Infectious Diseases Research Centre
Bangkok, Bangkok, 10330, Thailand